I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 3 studies | 36% ± 10% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 3 studies | 36% ± 10% |
Insufficient scRNA-seq data for expression of STYK1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 95% | 910.95 | 232 / 245 | 100% | 27.20 | 502 / 502 |
| lung | 70% | 83.06 | 405 / 578 | 92% | 9.84 | 1058 / 1155 |
| stomach | 74% | 498.99 | 264 / 359 | 85% | 6.81 | 244 / 286 |
| bladder | 62% | 258.33 | 13 / 21 | 93% | 10.83 | 469 / 504 |
| intestine | 55% | 581.32 | 528 / 966 | 92% | 9.88 | 486 / 527 |
| breast | 64% | 130.58 | 292 / 459 | 76% | 5.99 | 852 / 1118 |
| esophagus | 41% | 319.51 | 586 / 1445 | 95% | 9.26 | 174 / 183 |
| ureter | 0% | 0 | 0 / 0 | 100% | 6.39 | 1 / 1 |
| tonsil | 0% | 0 | 0 / 0 | 93% | 9.77 | 42 / 45 |
| pancreas | 2% | 1.31 | 5 / 328 | 91% | 11.76 | 162 / 178 |
| uterus | 9% | 16.10 | 16 / 170 | 80% | 10.30 | 369 / 459 |
| brain | 58% | 263.63 | 1525 / 2642 | 22% | 1.44 | 157 / 705 |
| spleen | 78% | 113.48 | 189 / 241 | 0% | 0 | 0 / 0 |
| skin | 70% | 91.23 | 1268 / 1809 | 1% | 0.05 | 5 / 472 |
| ovary | 3% | 2.03 | 5 / 180 | 49% | 2.03 | 209 / 430 |
| peripheral blood | 22% | 29.02 | 207 / 929 | 0% | 0 | 0 / 0 |
| kidney | 17% | 19.27 | 15 / 89 | 5% | 0.32 | 48 / 901 |
| adipose | 22% | 20.82 | 264 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 14% | 0.30 | 4 / 29 |
| thymus | 5% | 4.49 | 32 / 653 | 4% | 0.14 | 23 / 605 |
| liver | 0% | 0 | 0 / 226 | 4% | 0.25 | 18 / 406 |
| blood vessel | 4% | 3.98 | 53 / 1335 | 0% | 0 | 0 / 0 |
| adrenal gland | 1% | 0.74 | 2 / 258 | 2% | 0.08 | 4 / 230 |
| muscle | 1% | 0.85 | 5 / 803 | 0% | 0 | 0 / 0 |
| heart | 0% | 0.11 | 1 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006468 | Biological process | protein phosphorylation |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0004713 | Molecular function | protein tyrosine kinase activity |
| GO_0004715 | Molecular function | non-membrane spanning protein tyrosine kinase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0005524 | Molecular function | ATP binding |
| Gene name | STYK1 |
| Protein name | Serine/threonine/tyrosine kinase 1 Alternative protein STYK1 Tyrosine-protein kinase STYK1 (EC 2.7.10.2) (Novel oncogene with kinase domain) (Protein PK-unique) (Serine/threonine/tyrosine kinase 1) |
| Synonyms | NOK |
| Description | FUNCTION: Probable tyrosine protein-kinase, which has strong transforming capabilities on a variety of cell lines. When overexpressed, it can also induce tumor cell invasion as well as metastasis in distant organs. May act by activating both MAP kinase and phosphatidylinositol 3'-kinases (PI3K) pathways (By similarity). . |
| Accessions | F5H366 F5H4G3 ENST00000541561.1 F5GZF6 ENST00000075503.8 ENST00000542924.1 L8ECH9 F5H2I9 ENST00000542562.5 H0YGL5 ENST00000538867.5 ENST00000535345.5 Q6J9G0 |
